A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies

By sjmartinez • January 12, 2025

Ribrag V, Iglesias L, De Braud F, Ma B, Yokota T, Zander T, Spreafico A, Subbiah V, Illert AL, Tan D, Santoro A, Munster PN, Suehiro Y, Wang Y, Ji DM, Chen S, Beltz K, Suenaga N, Ramkumar T, Luo F, Lai C, Wainberg ZA. A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies. Eur J Cancer. 2024 Nov 16;216:115122. doi: 10.1016/j.ejca.2024.115122. Epub ahead of print. PMID: 39793445.

Tags: DLBCL, EED, ES, Hematology/Oncology, MAK683, PRC2, Publications

Related Posts

Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Hwang S, Shin DJ, Kang B, Kang H, Lee SH, Kim JS, Joung JG, Jain S, Olsen S, Becker L, Finn RS, Llovet JM, Kim[...]

KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy

Rugo HS, Cescon DW, Robson ME, Im SA, Dalenc F, Yañez Ruiz E, Reyes-Cosmelli F, Walshe JM, Im YH, Kulyk S, Dudnichenko O, Llinás-Quintero N,[...]

Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma: A Nonrandomized Clinical Trial

Nikitas J, Kendal JK, Savjani RR, Jackson N, Peterson N, Deng J, Hernandez J, Chong N, Singh AS, Chmielowski B, Federman NC, Crompton JG, Kadera[...]